Loading...
•
Jun 30, 2020
Exelixis Q2 2020 Earnings Report
Exelixis reported second quarter results, with total revenues of $259.5 million and GAAP diluted EPS of $0.21.
Key Takeaways
Exelixis announced its second quarter 2020 financial results, with total revenues reaching $259.5 million. The company highlighted positive top-line results from the CheckMate -9ER study and progress in its clinical development programs.
Total revenues for the quarter were $259.5 million, compared to $240.3 million for the comparable period in 2019.
GAAP net income for the quarter was $66.8 million, or $0.21 per share, diluted.
Non-GAAP net income for the quarter was $79.4 million, or $0.25 per share, diluted.
Cash and investments were $1.5 billion at June 30, 2020, compared to $1.4 billion at December 31, 2019.
Exelixis
Exelixis
Exelixis Revenue by Segment
Revenue by Segment
CABOMETYX Revenue
CapyFin.comCOMETRIQ Revenue
CapyFin.comLicense Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Exelixis provided updated financial guidance for fiscal year 2020.
Positive Outlook
- Total revenues: $900 million - $950 million
- Net product revenues: $725 million - $775 million
- Cost of goods sold: 4% - 5% of net product revenues
- Cash and investments: $1.5 billion - $1.6 billion
- Effective tax rate: 17% - 19%
Challenges Ahead
- Research and development expenses: $500 million - $550 million
- Includes $25 million of non-cash stock-based compensation expense.
- Selling, general and administrative expenses: $250 million - $270 million
- Includes $40 million of non-cash stock-based compensation expense.
- This cash guidance does not include any potential new business development activity, which remains a key priority for Exelixis as it continues to build toward becoming a multi-product oncology company.